Main Article Content
Background. In modern international guidelines, there are not distinguished criteria for the evaluation of clinical symptoms, including somatic, neurological status, although almost all neuroendocrinologists acknowledge the presence exactly of heterospecific complaints and symptoms in patients with organic hyperprolactinemia. Treatment of organic hyperprolactinemia is aimed at achieving recovery of normal levels of the biologically active prolactin (PRL) and a reduction in adenoma volume. The objective of the study — to investigate the clinical and hormonal effectiveness of different modes of suppressive cabergoline therapy in patients with prolactinoma during 12 months. Materials and methods of the study. 61 patients with prolactinoma (PROL) (52 women and 9 men) aged 16–66 years were examined and underwent 12-month course of treatment by selective dopamine agonist cabergoline (CAB). The total duration of the disease ranged from 1 to 60 months, average one — 12.3 ± 10.1 months. 40 women treated with CAB had microPROL, 12 — macro- and giant PROL. 2 men had microadenoma, 7 — macroadenoma. PROL was verified using magnetic resonance imaging. PRL blood levels (ng/mL) were determined by enzyme-linked immunosorbent assay on automated analyzer StatFax 2100 (Awareness Technology, USA) by means of commercial ELISA reagent kit (DRG Diagnostics, USA). We have used two modes of therapy: first one — the mode of gradual increase of CAB dose, starting from 0.5 mg a week, with subsequent control of the PRL blood level every 4 weeks and titration of the dose if necessary (increase in a week dose by 0.25–0.5 mg). Second one — the mode of high starting doses on the basis of the following: the quantity of CAB tablets (0.5 mg) corresponded to the rate of increased PRL blood levels in relation to the upper limit of age norm, but no more than 4 mg (8 tablets) a week. The statistical data analysis was carried out using program package Statgraphics Plus for Windows 3.0 (Manugistic Inc. USA). Results. We have proposed an integrated scoring system to assess the clinical and hormonal effectiveness of CAB suppressive therapy in patients with organic hyperprolactinemia, which enables at all stages of follow-up to correct treatment, to assess the possible risks from the use of high doses of the drug and to optimize the selection of an adequate dose. The optimal mode of therapy with cabergoline in patients with microprolactinoma is the regimen of gradually increasing doses, the positive clinical and hormonal effect of which is observed in 80 % of patients 3 months after initiation of treatment. Conclusions. Administration of high starting doses of cabergoline in patients with macro- and giant prolactinomas enables in a short span of time (in 1 month) to achieve reliable positive dynamics of the indicators of neurological, performance and hormonal status compared with the group of patients receiving therapy in the mode of gradually increasing doses of the drug.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Aron D, Howlett T. Pituitary incidentaloma // Endocrinol. Metabol. Clin. North. Am. 2000; 29: 205-21.
Mindermann T, Wilson CB. Age-related and gender-related occurrence 251 of pituitary adenomas // Clin. Endocrinol. (Oxf.). 1994; 41(3): 359-64.
Davis JR, Farrell WE, Clayton RN. Pituitary tumors // Reproduction. 2001; 121(3): 363-71.
Beckers A, Adam C, Ciccarelli A. Approaching the true prevalence of pituitary tumors // ENEA Congress. 2004; Abstr. 23.
Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary // J. Clin. Invest. 2003; 112: 1603-18.
Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas // Endocrinol. Rev. 2006; 27: 485-534.
Cannavò S, Curtò L, Squadrito S. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma // J. Endocrinol. Invest. 1999; 22: 354-59.
Colao A, Di Sarno A, Cappabianca P. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia // N. Engl. J. Med. 2003; 349: 2023-33.
Muratori M., Arosio M, Gambino G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients // J. Endocrinol. Invest. 1997; 20: 537-46.
Crosignani PG. Current treatment issues in female hyperprolactinaemia: Review // Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 4:13.
Casanueva F, Molitch M, Schlechte J. Guidelines of the pituitary Society for the diagnosis and management of prolactinomas // Clin. Endocrinol. 2006; 65: 265-73.
Abboud СН, Ebersold M. Prolactinomas // Diagnosis and Management Pituitary Tumors. 2001: 279-94.
Armitage P, Berry G. Statistical Methods in Medical Research. – Cambridge: University Press, 1994. – 620 p.